Fasudil

Fasudil is a synthetic drug from the group of Rho-kinase inhibitors (ROCK inhibitors). It was developed in Japan and has been in clinical use there since the 1990s. The active agent is mainly used in the treatment of cerebral vasospasms after subarachnoid hemorrhage, a complication that can occur after brain aneurysms. Through its vasodilating and vessel-protecting properties, Fasudil counteracts the dangerous narrowing of cerebral arteries. Beyond this main indication, Fasudil is increasingly being investigated in medical research, as Rho-kinase enzymes are involved in many cellular processes. Accordingly, the active agent opens up potential perspectives in a wide range of disease areas – from cardiovascular diseases to neurodegenerative conditions.

What benefits does Fasudil offer for health?

The medically relevant benefits of Fasudil are diverse, and investigations into various effects have been conducted. So far, however, research has concentrated primarily on the following areas:

  • Pulmonary hypertension (PH): In studies, Fasudil demonstrably lowered pulmonary vascular resistance and improved hemodynamics in patients with PH. In addition, it reduced both the mean pulmonary arterial pressure (mPAP) and the systolic pulmonary artery pressure (PASP). Furthermore, Fasudil was able to increase physical exercise capacity, as measured by the 6-minute walk distance (6MWD), and improve lung function, as reflected in the forced expiratory volume in one second (FEV1) (1,2).
  • Neurological diseases (stroke & Alzheimer's): In acute ischemic stroke, Fasudil protects against damage to the blood-brain barrier by increasing the expression of proteins responsible for the stability of the tight junctions between endothelial cells. It also reduces neuronal cell death and inflammatory processes associated with diabetic stroke by inhibiting the NLRP3 signaling pathway. In models of Alzheimer's disease, Fasudil likewise shows neuroprotective effects by reducing neuroinflammatory processes and attenuating memory impairments (3,4,5).
  • Anti-inflammatory and immunomodulating effects: In animal models, including septic shock, Fasudil has shown anti-inflammatory properties. It inhibited the migration of leukocytes, reduced systemic inflammatory responses, and protected against damage to the endothelium. Furthermore, Fasudil is potentially capable of suppressing the proliferation and infiltration of T cells (5,6).

How does Fasudil work in the body?

The effect of Fasudil is based on the selective inhibition of Rho-kinase (ROCK), an enzyme that plays central roles in cellular signal transduction (6)

Are there risks or side effects?

  • Common side effects: Headaches, facial flushing, a drop in blood pressure, and nausea can occur.
  • Specialized use: Fasudil is usually administered intravenously and used only under medical supervision in a hospital.
  • Unclear long-term safety: Comprehensive clinical data are not yet available for many of the potential new fields of application.

Conclusion

Fasudil is a significant Rho-kinase inhibitor that is used successfully, primarily in Japan, for the treatment of vasospasms after subarachnoid hemorrhage. In research, it also shows promising approaches in the field of cardiovascular diseases and neurodegenerative conditions. Despite its potential, the use of the active agent has so far remained limited to specific indications, and further research is still required for many new fields of application.

Sources:

  1. Bao, W., Cheng, M., Chen, X., Wang, T., Xu, D., Liao, H., Chen, L., Wen, F., He, J., & Chen, J. (2024). Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis. Expert review of clinical pharmacology, 1–18. Advance online publication. https://doi.org/10.1080/17512433.2024.2404688
  2. Kojonazarov, B., Myrzaakhmatova, A., & Sooronbaev, T. (2012). Effects of fasudil in patients with high-altitude pulmonary hypertension. European Respiratory Journal, 39(2), 496–498. https://doi.org/10.1183/09031936.00095211
  3. Salman, M., Shahzad, H., Gangaraju, R., & Ishrat, T. (2025). Fasudil mitigates diabetes-associated cognitive decline and enhances neuroprotection by suppressing NLRP3/Caspase-1/GSDMD signaling in a stroke mouse model. Experimental Neurology, 389, 115268. https://doi.org/10.1016/j.expneurol.2025.115268
  4. Sato, K., Nakagawa, S., Morofuji, Y., Matsunaga, Y., Fujimoto, T., Watanabe, D., Izumo, T., Niwa, M., Walter, F. R., Vigh, J. P., Santa-Maria, A. R., Deli, M. A., & Matsuo, T. (2022). Effects of fasudil on blood-brain barrier integrity. Fluids and barriers of the CNS, 19(1), 43. https://doi.org/10.1186/s12987-022-00336-w
  5. Song, Y., Chen, X., Wang, L. Y., Gao, W., & Zhu, M. J. (2013). Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats. CNS neuroscience & therapeutics, 19(8), 603–610. https://doi.org/10.1111/cns.12116
  6. Liu, H., Pan, Z., Ma, X., Cui, J., Gao, J., Miao, Q., Zhu, Z., Chen, X., & Su, S. (2022). ROCK inhibitor fasudil reduces the expression of inflammatory factors in LPS-induced rat pulmonary microvascular endothelial cells via ROS/NF-κB pathway. BMC pharmacology & toxicology, 23(1), 24. https://doi.org/10.1186/s40360-022-00565-7